|
 
Last update: |
 |
|
|
05-Jun-2015
|
 |
|
|
Arch Hellen Med, 32(3), May-June 2015, 295-301 REVIEW The efficacy and safety of novel anti-obesity therapies A.K. Papazafiropoulou,1 N. Papanas,2 A. Melidonis1 |
Obesity is a chronic disease with a high prevalence in both developed and developing countries. Lifestyle interventions, such as restricting calorie consumption and increasing physical activity, continue to be the cornerstone of weight-reduction programs. Novel anti-obesity drug therapies are currently gaining in importance. These include lorcaserin (a selective serotonin agonist), phentermine/topiramate combination, naltrexone/bupropion combination (acting on the hypothalamus), and liraglutide, an established anti-diabetic agent which suppresses the appetite. This is a brief review of the evidence on the role of these anti-obesity drugs in the management of obesity.
Key words: Bupropion, Liraglutide, Lorcaserin, Naltrexone, Obesity, Phentermine, Topiramate.
